Abstract
Biologics in development for the treatment of moderate to severe plaque-type psoriasis are discussed in this article. Immunomodulators used as therapeutic, pathogenic probes will continue to identify targets that play primary roles in the pathogenesis of psoriasis.
MeSH terms
-
Antibodies, Monoclonal / therapeutic use*
-
Cytokines / immunology
-
Humans
-
Immunosuppressive Agents / therapeutic use*
-
Psoriasis / drug therapy*
-
Psoriasis / immunology*
-
Skin / immunology
-
T-Lymphocytes / immunology
Substances
-
Antibodies, Monoclonal
-
Cytokines
-
Immunosuppressive Agents